By Christopher Kuo
Summit Therapeutics shares fell after the company's losses widened in the first quarter.
Shares of the biopharmaceutical oncology company fell 22% on Friday to $16.73. The company's shares are down 4.6% year to date.
The company on Thursday posted a first-quarter loss of $189.4 million, or 24 cents a share, compared with a loss of $62.9 million, or 9 cents a share, a year earlier.
Adjusted per share earnings came in at a loss of 15 cents. Analysts polled by FactSet expected adjusted per share earnings loss of 17 cents a share.
Write to Christopher Kuo at chris.kuo@wsj.com
(END) Dow Jones Newswires
May 01, 2026 15:23 ET (19:23 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.